MimiVax and Roswell Park open phase 2 trial of SurVaxM for metastatic neuroendocrine tumours
Study expands evaluation of survivin‑targeting vaccine
Read More
Author: John Pinching
Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
UK spin‑out speeds up development and reduces animal testing
Read More
Survodutide delivers 16.6% weight loss in major phase 3 obesity trial
Boehringer Ingelheim reports significant reductions in weight
Read More
Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
Partnership to support selection of first neoantigen therapy candidate
Read More
BioDuro and CTI Biotechnology form partnership to accelerate preclinical drug development
Collaboration aims to create integrated platform from discovery to IND submission
Read More- UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies
- Calla Lily Clinical Care begins dosing in trial of intravaginal platform for threatened miscarriage
- Palisade Bio reports phase 1a/b data showing colon‑targeted exposure
- MimiVax and Roswell Park open phase 2 trial of SurVaxM for metastatic neuroendocrine tumours
- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
